Highlights fourth quarter 2025:
• Q4 revenues reached USD 55.2 million, an increase of 6% year-over-year (YoY), with adjusted EBITDA of USD 10.6 million, up 66% from the prior year.
• Human Health Ingredients delivered USD 32.7 million in revenue, up 28% YoY, supported by strong volume growth and improved price mix. Adjusted EBITDA increased 59% to USD 14.1 million.
• Consumer Health Products generated USD 26.9 million in revenue, down 8% YoY. EBITDA improved on better gross margins and continued cost control.
• Emerging Business reported USD 2.0 million in revenue, stable compared to previous quarters. Adjusted EBITDA was USD -0.5 million
• Large new customer for krill oil fully onboarded in quarter with strong initial performance
• Following recent interest in the Human Health Ingredient business unit, the Company has engaged advisers to support exploring alternatives and work towards a transaction in 2026
“We delivered another solid quarter with continued improvement in profitability, driven primarily by strong performance in Human Health Ingredients. It was also particularly exciting with launch of a new krill oil brand in Costco during the quarter, which has delivered great performance in the initial phase.”, said Matts Johansen, CEO of Aker BioMarine.
Segment performance
Human Health Ingredients continued its strong trajectory with 28% revenue growth year-over-year, driven by higher volumes and an improved price mix. Krill oil equivalent revenues increased 28%, supported by strong demand. Adjusted EBITDA increased significantly year-over-year on improved gross margins and effect of operational leverage. During the quarter, the company supplied significant volumes of Superba Krill Oil to new customers, including a successful product listing at Costco.
Consumer Health Products reported an 8% decline in revenue year-over-year, reflecting lower-than-expected demand growth and continued pressure in drugstore channels. Revenues remained broadly stable through 2025, albeit at lower levels than in 2024. EBITDA improved compared to last year, supported by improved gross margins, disciplined cost control and continued focus on SG&A efficiency.
Outlook
The Human Health Ingredients segment sees continued year-over-year growth, supported by good underlying demand in multiple markets. For the first quarter of 2026, krill oil revenues are expected to increase by 15-30% year-over-year. In Consumer Health Products, revenues are expected to follow market growth over time. The Emerging Business segment remains on track toward cash break-even, with active engagement in potential transactions. At the corporate level, the company has established a new, leaner cost base and is executing on initiatives to further improve financial and operational efficiency.
Following recent interest in the Human Health Ingredient business unit, the Company has engaged Jefferies and Houlihan Lokey as investment banks to support the Company in exploring alternatives and work towards a transaction in 2026.
AKBM is adapting to market trends through productivity and cost measures while actively assessing the potential impact of increased macroeconomic uncertainty and new tariffs.
Attached is the quarterly presentation for Q4. Group reported financial figures can be downloaded in an excel from the company’s investor page: Investor - Analyst information.
At 09:00 CET today, the management hosts a webcast. The webcasted presentation will be in English. To join, please use the link www.akerbiomarine.com/webcast.
A replay of the presentation will be made available soon after the presentation at the same web address.
For further information, please contact
Christopher Robin Vinter, VP Strategic Finance & IR
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.